ArticleScientific reports2025
Diminished lung function mediating the associations between blood levels of volatile organic compounds and respiratory morbidity and mortality.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Exposure to individual volatile organic compound (VOC) is associated with reduced lung function and increased respiratory disease (RD) morbidity and mortality. However, whether a mediating pathway among exposure to VOC mixtures, diminished lung function, and increased RD risk exists statistically remains undisclosed. This study analyzed 6156 adults (aged ≥ 18) from National Health and Nutrition Examination Survey (NHANES) 2007-2012. We applied Bayesian Kernel Machine Regression (BKMR) models to analyze the association between VOCs and lung function, and then used mediation models to assess lung function's role in RD morbidity and mortality. Changes of forced vital capacity (FVC) accounted for 12.22%, 29.76%, and 17.34% of the association of nitromethane with asthma [0.004 (0.002, 0.005), P < 0.001], emphysema [0.001 (0.001, 0.002), P < 0.001], and chronic bronchitis [0.003 (0.002, 0.005), P < 0.001], respectively. We also observed significant indirect effect of nitromethane with all-cause mortality through the mediation of FVC [0.042 (0.018, 0.066), P < 0.001, proportion = 23.13%] and forced expiratory volume at 1 s (FEV
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.